David R Nelson Selected Research

drotrecogin alfa activated (Xigris)

5/2011	Is worsening multiple organ failure the cause of death in patients with severe sepsis?
1/2008	Protein C: a potential biomarker in severe sepsis and a possible tool for monitoring treatment with drotrecogin alfa (activated).
1/2008	Influence of enrollment sequence effect on observed outcomes in the ADDRESS and PROWESS studies of drotrecogin alfa (activated) in patients with severe sepsis.
6/2007	International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: 28-day survival and safety.
1/2007	The protein C pathway: implications for the design of the RESPOND study.
5/2006	International INtegrated Database for the Evaluation of severe sePsis and drotrecogin alfa (activated) THerapy: component trials and statistical methods for INDEPTH.
1/2006	Drotrecogin alfa (activated): current evidence supports treatment for severe sepsis patients with a high risk of death.
11/2004	Hospital mortality and resource use in subgroups of the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) trial.
5/2004	Effect of factor V Leiden polymorphism in severe sepsis and on treatment with recombinant human activated protein C.
5/2004	Leukocyte and endothelial cell interactions in sepsis: relevance of the protein C pathway.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

David R Nelson Research Topics

Disease

62	Infections 01/2022 - 11/2002
44	Chronic Hepatitis C 01/2022 - 01/2003
39	Fibrosis (Cirrhosis) 10/2021 - 11/2002
35	Hepatitis C 01/2021 - 11/2002
16	Sepsis (Septicemia) 07/2013 - 07/2003
12	Hepatocellular Carcinoma (Hepatoma) 10/2019 - 05/2003
9	Liver Diseases (Liver Disease) 12/2021 - 10/2003
9	Neoplasms (Cancer) 11/2018 - 03/2004
7	End Stage Liver Disease 01/2021 - 05/2006
6	Virus Diseases (Viral Diseases) 04/2015 - 01/2003
5	Hepatitis 12/2021 - 11/2002
5	Body Weight (Weight, Body) 04/2014 - 10/2008
5	Hepatitis B 01/2011 - 08/2005
5	Inflammation (Inflammations) 01/2007 - 07/2003
4	Chronic Renal Insufficiency 10/2017 - 05/2006
4	Fatigue 05/2013 - 09/2010
3	Disease Resistance 12/2021 - 11/2018
3	Substance-Related Disorders (Drug Abuse) 01/2021 - 01/2017
3	Type 2 Diabetes Mellitus (MODY) 01/2018 - 07/2011
3	Liver Cirrhosis (Hepatic Cirrhosis) 10/2017 - 08/2011
3	Anemia 11/2013 - 07/2007
3	Nausea 05/2013 - 04/2013
3	Starvation 05/2013 - 01/2000
2	Chronic Hepatitis (Chronic Active Hepatitis) 01/2022 - 08/2010
2	Tuberculosis (Tuberculoses) 07/2020 - 02/2019
2	Myocardial Infarction 01/2018 - 01/2018
2	Stroke (Strokes) 01/2018 - 01/2018
2	Lyme Disease (Disease, Lyme) 02/2016 - 01/2010
2	Hemorrhagic Septicemia (Haemorrhagic Septicemia) 10/2013 - 05/2006
2	Hemolysis 10/2013 - 09/2009
2	Neutropenia 06/2013 - 01/2012
2	Headache (Headaches) 05/2013 - 05/2013
2	Rheumatoid Arthritis 03/2013 - 10/2011
2	Persistent Infection 09/2011 - 09/2005
2	Liver Neoplasms (Liver Cancer) 04/2011 - 03/2004
2	Disease Progression 09/2009 - 10/2003
2	Protein C Deficiency 01/2006 - 05/2004

Drug/Important Bio-Agent (IBA)

36	Ribavirin (Virazole)FDA LinkGeneric 10/2021 - 11/2002
35	Antiviral Agents (Antivirals)IBA 01/2022 - 11/2002
23	InterferonsIBA 09/2019 - 02/2004
20	SofosbuvirIBA 12/2019 - 04/2013
13	Pharmaceutical PreparationsIBA 02/2019 - 11/2004
12	drotrecogin alfa activated (Xigris)FDA Link 05/2011 - 07/2003
10	RNA (Ribonucleic Acid)IBA 12/2016 - 11/2002
9	Proteins (Proteins, Gene)FDA Link 12/2021 - 01/2000
9	Protein CIBA 01/2008 - 05/2004
8	Protease Inhibitors (Protease Inhibitor)IBA 10/2017 - 01/2011
8	Interferon-alpha (Interferon Alfa)IBA 02/2009 - 05/2003
7	AlbuminsIBA 01/2020 - 01/2006
7	Biomarkers (Surrogate Marker)IBA 01/2018 - 07/2003
5	NucleotidesIBA 12/2021 - 05/2013
5	telaprevirIBA 04/2015 - 09/2011
4	sofosbuvir drug combination ledipasvirIBA 01/2022 - 12/2016
4	glecaprevir and pibrentasvirIBA 01/2021 - 10/2017
4	BilirubinIBA 01/2020 - 12/2016
4	dasabuvirIBA 01/2019 - 01/2014
4	ombitasvirIBA 01/2019 - 01/2014
4	paritaprevirIBA 01/2019 - 01/2014
4	Ritonavir (Norvir)FDA Link 01/2019 - 01/2014
4	daclatasvirIBA 11/2016 - 01/2014
4	peginterferon alfa-2a (Pegasys)FDA Link 06/2013 - 10/2008
4	Alanine Transaminase (SGPT)IBA 11/2012 - 08/2005
4	Interferon alpha-2 (Roferon-A)FDA Link 10/2010 - 11/2002
3	grazoprevirIBA 01/2022 - 10/2015
3	elbasvirIBA 01/2022 - 10/2015
3	ledipasvirIBA 11/2018 - 04/2014
3	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 10/2017 - 11/2007
3	N- (3- amino- 1- (cyclobutylmethyl)- 2,3- dioxopropyl)- 3- (2- ((((1,1- dimethylethyl)amino)carbonyl)amino)- 3,3- dimethyl- 1- oxobutyl)- 6,6- dimethyl- 3- azabicyclo(3.1.0)hexan- 2- carboxamideIBA 02/2015 - 11/2013
3	Sorafenib (BAY 43-9006)FDA Link 04/2013 - 04/2011
3	Hepatitis B Surface Antigens (HBsAg)FDA Link 01/2011 - 01/2006
3	albinterferon alfa-2bIBA 10/2010 - 02/2009
3	Human Serum Albumin FDA LinkGeneric 10/2010 - 01/2006
2	CarbonIBA 02/2019 - 01/2003
2	DNA (Deoxyribonucleic Acid)IBA 11/2018 - 11/2012
2	SimeprevirIBA 01/2018 - 02/2016
2	pibrentasvirIBA 10/2017 - 10/2017
2	glecaprevirIBA 10/2017 - 10/2017
2	CreatinineIBA 02/2015 - 05/2006
2	Peptides (Polypeptides)IBA 10/2014 - 10/2010
2	TabletsIBA 04/2014 - 04/2014
2	Hemolysin Proteins (Hemolysins)IBA 10/2013 - 06/2008
2	Rituximab (Mabthera)FDA Link 03/2013 - 01/2010
2	Biological ProductsIBA 10/2011 - 08/2009
2	gamma-Glutamyltransferase (gamma-Glutamyl Transpeptidase)IBA 08/2011 - 10/2010
2	Phosphotransferases (Kinase)IBA 04/2011 - 08/2004
2	Interleukin-10 (Interleukin 10)IBA 08/2010 - 10/2003
2	Cyclosporine (Ciclosporin)FDA LinkGeneric 01/2010 - 01/2006
2	ProdrugsIBA 09/2009 - 07/2007
2	taribavirin (viramidine)IBA 09/2009 - 07/2007
2	Virulence Factors (Pathogenicity Factors)IBA 06/2008 - 05/2006
2	Interleukin-6 (Interleukin 6)IBA 01/2007 - 05/2004
2	EndotoxinsIBA 05/2004 - 03/2004

Therapy/Procedure

56	Therapeutics 01/2021 - 11/2002
23	Liver Transplantation 10/2019 - 11/2002
5	Transplantation 07/2013 - 01/2005
3	Aftercare (After-Treatment) 12/2019 - 02/2004
3	Drug Tapering 11/2013 - 02/2009
2	Duration of Therapy 01/2021 - 02/2016
2	Drug Therapy (Chemotherapy) 04/2015 - 05/2008
2	Bone Marrow Transplantation (Transplantation, Bone Marrow) 05/2008 - 01/2006